drugset / Trial / NCT00771420
A Single Dose Study of the CAM-3001 in Patients With Rheumatoid Arthritis
RandomizedParallel-groupDouble-blindTreatment
Summary
Investigate safety and tolerability of the escalating dose of CAM-3001 in patients.
Timeline
- Start
- 2008-10
- Primary completion
- 2008-12
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mavrilimumab | Monoclonal antibody | 0.01 mg/kg | Intravenous |
| Comparator | Mavrilimumab | Monoclonal antibody | 0.03 mg/kg | Intravenous |
| Comparator | Mavrilimumab | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Comparator | Mavrilimumab | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Comparator | Mavrilimumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Comparator | Mavrilimumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Comparator | Mavrilimumab | Monoclonal antibody | 10 mg/kg | Intravenous |